Biomedical subjects

C Atalay

Publications and source records attributed to C Atalay.

16 recordsLinked to original sources

PubMed2005

Urodynamic evaluation of lower urinary tract function in relation to total abdominal hysterectomy.

This study was performed to evaluate lower urinary tract functions in asymptomatic patients by urodynamic measurements after total abdominal hysterectomy and bilateral salpingo-oophorectomy. Twenty asymptomatic patients who had undergone hysterectomy for benign diseases were included in the study and urodynamic measurements were performed before and 6 weeks after total abdominal hysterectomy and bilateral salpingo-oophorectomy. There was no postoperative difference in first urge, normal urge, urgency and maximum bladder capacity but average urethral length, functional urethral length and maximum urethral closing pressure were decreased and also bladder discharging time was increased. Voided volume and residual urine volume were unchanged. It was concluded that total abdominal hysterectomy and bilateral salpingo-oophorectomy did not change the postoperative bladder loading functions in asymptomatic patients but that significant changes occurred in urethral functions.

Journal Article↗

PubMed2005

The role of anti-CENP-B and anti-SS-B antibodies in breast cancer.

A close relationship between autoimmunity and malignant diseases has been supposed for a long time. In clinical practice, anti-SS-B and anti-CENP-B antibodies are used as serologic markers for autoimmune diseases. In this study, anti-SS-B and anti-CENP-B autoantibodies were studied in breast cancer patients and compared to a control group surgically treated due to benign diseases. These antibodies were evaluated by enzyme linked immunoassay and serum values >10 U/ml were accepted as positive. Fifty-five patients with breast cancer and 25 patients with benign diseases were prospectively included in the study. In the breast cancer group, both anti-CENP-B (33% vs. 8%) and anti-SS-B (44% vs. 24%) autoantibodies had higher positivity compared to the control group, but this difference reached statistical significance only for anti-CENP-B antibodies (p=0.02). Besides, anti-SS-B positivity was detected more frequently in breast cancer patients with axillary involvement (63% vs. 24%) (p=0.006) and increased as the number of involved lymph nodes increased in the axilla (p=0.03). Although the clinical significance of autoantibody detection in cancer patients is still not clear, autoantibodies especially detected in individuals without proven autoimmune diseases needs to be thoroughly evaluated for early diagnosis and treatment of various cancers.

Adult↗

PubMed2005

A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.

Adjuvant chemotherapy increases disease-free survival (DFS) and overall survival (OS) following surgery for breast cancer. However, debates concerning the type of adjuvant chemotherapy continue. The effect of adjuvant chemotherapy on loco-regional recurrence-free survival (LFS) was also reported. The present study was undertaken to compare the results of adjuvant FAC (5-fluorouracil, Doxorubicin, Cyclophosphamide) and CMF (Cyclophosphamide, Methotrexate, 5-fluorouracil) chemotherapy on DFS, OS and LFS for node positive breast carcinoma treated with mastectomy in a non-randomised setting. Data from 688 consecutive lymph node positive breast cancer patients who underwent radical or modified radical mastectomy and received adjuvant FAC (600/60/600 mgr/m2 for 6 cycles every three weeks) or CMF (600/40/600 mgr/m2 for 6 cycles on days land 8 every four weeks) chemotherapy were reviewed. The effect of FAC on DFS, OS and LFS as compared with CMF was analysed. Survival curves were generated by the Kaplan-Meier method, and a multivariate analysis was performed by the Cox proportional hazard model. Adjuvant FAC was found to improve DFS, OS and LFS. 5-year DFS, OS and LFS were longer for patients treated with FAC as compared to CMF (67% versus 53%, p < 0.001; 77% versus 66%, p < 0.001, and 97% versus 91%). Adjusted hazard ratio (HR) for potential risk factors and tamoxifen treatment showed that FAC treated patients much benefitted in terms of survival as compared to CMF treated patients (HR 0.53, CI 0.40-0.69 for DFS; HR 0.48, CI 0.35-0.65 for OS, and HR 0.33, CI 0.16-0.65 for LFS). In conclusion, adjuvant FAC improves DFS, OS and LFS as compared to CMF in node positive breast carcinoma patients treated with mastectomy.

Adult↗

PubMed2003

Prognostic factors affecting survival in male breast cancer.

Male breast cancer is an uncommon disease and most of the data concerning its treatment and prognostic factors have been obtained from studies spanning a long period of time during which the main concepts of treatment in breast cancer have changed. In the current study, patients affected with male breast cancer treated in the last decade with a multidisciplinary approach were reported from a single Institution. Fifty-five patients with male breast cancer treated between 1990 and 1998 were included in this study. The median follow-up period was 36 months. Five-year disease-free and overall survival were 44.5% and 72.9%, respectively. Patients' age, tumor size, axillary status, tumor type and treatment modalities such as surgery, chemotherapy, radiotherapy, and hormonotherapy were evaluated as possible prognostic factors affecting the disease-free and overall survival periods. In univariate analysis, tumor size, axillary status and extent of surgery were found to be affecting overall survival significantly whereas axillary status, tumor type, extent of surgery and chemotherapy affected disease-free survival. In multivariate analysis, axillary status, extent of surgery and tumor type were found as independent prognostic factors for overall survival and radiotherapy was added to these factors for disease-free survival. In conclusion, the approach to male breast cancer patients should be similar to that for female patients. Modified radical mastectomy should be the gold standard followed by combined adjuvant therapy individualized for patients due to axillary status, tumor size and type.

Analysis of Variance↗

PubMed2003

Gastroduodenal metastases in a clear cell sarcoma patient.

Clear cell sarcoma is a rare tumor with an unpredictable clinical course and usually poor prognosis. Almost all of the patients will have pulmonary metastases during the clinical course. Other more common metastatic sites are bones, lymph nodes, liver and spleen. Treatment of clear cell sarcoma is primarily surgical aiming to achieve uninvolved margins. Role of chemotherapy, radiotherapy and immunotherapy is controversial and remission of metastases has been reported rarely. In this study we report a case of clear cell sarcoma, with gastroduodenal and pulmonary metastases and remission of these metastases in response to chemotherapy.

Antineoplastic Combined Chemotherapy Protocols↗

PubMed2003

Serum Helicobacter pylori IgG and IgA levels in patients with gastric cancer.

The association between Helicobacter pylori and gastric cancer has been debated in the last decade and evidence for such a causal relationship has been claimed. This study aimed to detect the seroprevalence of Helicobacter pylori in patients with gastric cancer and compare it to the other cancer patients. In addition, the value of IgG and IgA in Helicobacter pylori detection was compared in patients with gastric cancer. Consecutive gastric and other cancer patients treated between 1999-2001 were prospectively studied. Serum Helicobacter pylori IgG and IgA levels were determined. Serological tests revealed IgA and IgG positivity as 53.9% and 50.9%, respectively, while 74.5% had positive results for either IgA or IgG. Serum IgA positivity was significantly higher in gastric cancer group compared to control group (p=0.02). In contrast, serum IgG positivity did not show a significant difference in both groups and either IgG or IgA seropositivity was significantly higher in patients with gastric cancer compared to control patients (p=0.04). This study revealed a higher seroprevalence of Helicobacter pylori in gastric cancer patients and IgA was a better predictor of Helicobacter pylori seropositivity in gastric cancer patients.

Adolescent↗

PubMed2002

Menstrual cycle and hormone receptor status in breast cancer patients.

Hormone receptors in normal breast tissue were reported to be under the influence of cyclic variations of serum hormones during the menstrual cycle. The current study aimed to demonstrate a similar relationship between the phase of the menstrual cycle and hormone receptor status in operable, premenopausal patients with breast cancer. Patients were prospectively categorized according to the first day of last menstrual period into clinically defined follicular/luteal, perimenstrual/mid-cycle and unopposed estrogen/rest of the cycle phases and hormonally defined follicular/luteal phases. Serum follicle-stimulating hormone, luteinizing hormone, estrogen and progesterone levels were determined on the day of the operation. Estrogen and progesterone receptors in the tissues were detected by immunohistochemistry. Eighty-eight consecutive premenopausal patients with breast cancer were included in the study. Estrogen and progesterone receptors were positive in 57 (64.8%) and 40 (70.2%) patients respectively. Forty-nine patients were in follicular, and 39 patients in luteal phases according to serum hormone levels. Estrogen receptor positivity was significantly higher in hormonally defined follicular phase (p=0.025) and also had a tendency to be higher in perimenstrual phase (p=0.048). In contrast, progesterone receptor status was found to be independent of the phases of the menstrual cycle. As a conclusion, hormone receptor status might change during different phases of the menstrual cycle due to a possible effect of the circulating hormones and if it is found as negative, should he re-evaluated concerning the phase of the menstrual cycle in which the operation was performed.

Adult↗

PubMed2002

Comparison of prognostic scoring system to tumor node metastases 1992 and 1997 staging systems in gastric cancer patients.

Tumor node metastases staging systems have been widely utilized to predict the prognosis of gastric cancer patients. The current study aimed to compare a prognostic scoring system to tumor node metastases 1992 and 1997 staging systems in predicting the outcome of resectable gastric cancer patients. Patients treated between 1996-1998 were retrospectively evaluated. Tumor depth in the gastric wall, anatomical location and number of metastatic lymph nodes, metastatic to retrieved lymph node ratio, extent of surgical resection, tumor location, type of lymph node dissection, macroscopic appearence and histologic type of tumor were recorded and patients were divided into groups I-III due to their scores. Patients were also staged according to both tumor node metastases systems. Survival data was analyzed by Kaplan-Meier method. For the comparison of power of the three systems in predicting survival, log-rank and Cox regression analysis were respectively used for univariate and multivariate analysis. 163 resectable gastric cancer patients were evaluated. Median follow-up and survival times were 26 and 23 months respectively. Overall 5-year survival was 37.6%. The number of patients in prognostic scoring groups I, II and III was 44, 109 and 10, respectively. According to tumor node metastases 1992 system, 13, 43, 101 and 6 patients were in stages I, II, III and IV while there were 13, 38, 78 and 34 patients in respective stages in tumor node metastases 1997 system. Although tumor node metastases 1992 (p=0.0088), 1997 (p=0.0029) and prognostic scoring systems (p=0.0006) significantly predicted the survival of patients in univariate analysis, prognostic scoring system was found to be superior compared to other two systems in multivariate analysis (p=0.0002). Prognostic scoring system is a practical, reliable and reproducible method that could be used as an adjunct to tumor node metastases systems in predicting survival of resectable gastric cancer patients.

Adult↗

PubMed1998

Treatment of bacterial vaginosis with oral or vaginal ornidazole, secnidazole and metronidazole.

OBJECTIVE: To evaluate the clinical efficacy and tolerance of oral or vaginal ornidazole, secnidazole and metronidazole or their combinations for treatment of bacterial vaginosis. METHOD: In an open, randomized, prospective study, 152 patients with bacterial vaginosis according to Amsel's criteria were included into the study. The patients were divided into eight groups: (1) oral ornidazole 2 x 500 mg/day for 5 days; (2) vaginal ornidazole 500 mg/day for 5 days; (3) oral and vaginal ornidazole for 5 days; (4) oral secnidazole 2 g in a single dose; (5) oral secnidazole 2 g in a single dose and vaginal ornidazole 500 mg/day for 5 days; (6) oral secnidazole 2 g in a single dose and vaginal metronidazole 2 x 500 mg/day for 7 days; (7) oral ornidazole 2 x 500 mg/day for 5 days and vaginal metronidazole 2 x 500 mg/day for 7 days; and (8) vaginal metronidazole 2 x 500 mg/day for 7 days. None of the partners received any treatment. RESULT: We found a 100% cure rate in both oral and vaginal ornidazole and oral secnidazole-vaginal metronidazole groups. CONCLUSION: Vaginal treatments including ornidazole and metronidazole are not as effective as both oral and vaginal drug combinations.

Administration, Intravaginal↗

PubMed1996

A retrospective study of 11 pregnant women with thermal injuries.

Out of 917 burn victims admitted to the Burn Unit of Ankara Numune Hospital between 1986 and 1994, the records of 11 pregnant patients were scrutinized retrospectively. All patients were classified by using the rule of 9's. Two maternal deaths (18%) occurred in patients with burns involving more than 50% of the skin surface area and there were four fetal deaths (36%) which occurred less than 72 h after the burns. These findings support the views that maternal and perinatal outcome is related to the burn severity (surface area + depth), to the presence or absence of complications and to the gestational age of the fetus. In view of the high perinatal mortality, in any patient with extensive burns who is more than 32 weeks pregnant, the fetus should be delivered soon after admission.

Adult↗

PubMed1996

Effects of aprotinin on plasma levels of neutrophil elastase and postoperative blood loss in cardiac surgery.

This study evaluated the effects of aprotinin on plasma levels of elastase, platelet count, fibrinogen levels and postoperative bleeding. Thirty cardiac surgery patients were randomly chosen for this study. The protease inhibitor aprotinin was given in high doses to 20 patients before and during cardiopulmonary bypass; 10 patients served as the control group. Mean patient age and body weight was similar in both groups. There were no significant inter-group differences in the total cardiopulmonary bypass and cross-clamp times. Mean (s.e.m.) elastase levels were significantly raised in the control group (161.9(2.57) micrograms/l) compared with the treated group (148.2(3.29) micrograms/l) at 30 min of cardiopulmonary bypass (P < 0.01) and rose even further at the end of cardiopulmonary bypass, after protamine infusion, and 24 h postoperatively (P < 0.001). Platelet counts decreased more in the control group (P < 0.001). Serum fibrinogen levels were significantly lower in the controls during and just after cardiopulmonary bypass (P < 0.01). Postoperative blood loss was significantly less in the aprotinin-treated patients (315(25) ml) compared with the controls (589(154) ml) (P < 0.05). Aprotinin appears to inhibit elastase release and decrease postoperative blood loss.

Adult↗

PubMedDate not supplied

Primary gastrointestinal tract lymphomas.

AIM: To evaluate the prognostic factors and treatment modalities affecting survival in patients with primary gastrointestinal tract lymphoma. MATERIAL AND METHODS: Gastrointestinal tract lymphoma patients were retrospectively studied. Age and sex of patients, location and histopathological grade of tumour, stage of disease, extent of surgical resection and chemotherapy were evaluated as prognostic factors. Effects of clinicopathological and treatment associated factors on disease-free and overall survival were calculated in univariate and multivariate analyses. RESULTS: On univariate analysis, disease stage (p = 0.002), extent of surgical resection (p = 0.003) and chemotherapy (p = 0.001) were found to be significantly affecting overall survival and none of the studied factors were found to be related with disease-free survival. Multivariate analysis revealed that grade of the tumour (p = 0.042) and chemotherapy (p = 0.028) significantly affected disease-free survival and disease stage (p = 0.013) and chemotherapy (p = 0.0003) were independent prognostic factors for overall survival. In addition, surgery and chemotherapy in combination, significantly increased overall survival compared to surgery or chemotherapy only. CONCLUSION: Early stage patients have a better survival and it could be prolonged if surgery with no residual disease is performed; adjuvant chemotherapy provides an additional benefit.

Adolescent↗

PubMedDate not supplied

Acupressure versus oxybutinin in the treatment of enuresis.

We aimed to assess the efficacy of acupressure for treating nocturnal enuresis, compared with oxybutinin. Acupressure was administered to 12 patients by their parents, who had been taught the technique. Pressure was applied at acupuncture points Gv4, Gv15, Gv20, B23, B28, B32, H7, H9, St36, Sp4, Sp6, Sp12, Ren2, Ren3, Ren6, K3 and K5. Twelve control patients received 0.4 mg/kg oxybutinin. Parents were asked to record incidences of bed-wetting and patients and/or parents completed a questionnaire 15 days and 1, 3 and 6 months after the start of treatment. Complete and partial responses after 6 months of treatment were seen in 83.3% and 16.7%, respectively, of patients treated with acupressure, and in 58.3% and 33.3%, respectively, of children who received oxybutinin. In conclusion, nocturnal enuresis can be partially treated by oxybutinin but acupressure could be an alternative non-drug therapy. Acupressure has the advantages of being non-invasive, painless and cost-effective.

Acupressure↗

PubMedDate not supplied

Identification of the culprit artery involved in inferior wall acute myocardial infarction using electrocardiographic criteria.

We tested whether particular electrocardiogram (ECG) changes can identify the right coronary (RCA) or left circumflex (LCX) artery as the responsible vessel in inferior wall acute myocardial infarction (AMI) in 73 patients. A standard 12-lead ECG was performed within 6 h of onset of chest pain. Coronary angiography was performed between 1 week and 6 weeks after the infarction. RCA and LCX lesions were detected in 53 and 20 patients, respectively. The most useful ECG parameters for implicating the RCA were a higher ST elevation in lead III than lead II (specificity 94%, sensitivity 86%) and an S/R wave ratio > 0.33 plus ST segment depression > 1 mm in lead aVL (specificity 94%, sensitivity 92%). Absence of these criteria was associated with LCX occlusion (specificity 100%, sensitivity 87%). These results indicate that composite ECG criteria are useful in predicting the artery involved in inferior wall AMI.

Adult↗

PubMedDate not supplied

Effects of trimetazidine on lipid peroxidation, antioxidant enzyme activities and plasma brain natriuretic peptide levels in patients with chronic cor pulmonale.

An oxidant/antioxidant imbalance in favour of oxidants appears to occur in chronic cor pulmonale (CCP). Oxidative stress could also be a critical event in the pathogenesis of this condition. Trimetazidine (TMZ) has antioxidant properties and may affect the utilization of oxygen radicals. We investigated the effect of TMZ (20 mg three times daily, orally) on activities of erythrocyte malondialdehyde (MDA) and catalase (eCAT), erythrocyte and plasma glutathione peroxidase (GSH-Px) and plasma superoxide dismutase (pSOD) in CCP patients. We also assessed changes in plasma levels of brain natriuretic peptide (BNP) with TMZ therapy. Sixty CCP patients with significantly higher MDA and markedly lower pSOD, eCAT and GSH-Px (erythrocyte) activities than 24 healthy controls were randomly allocated to receive routine treatment or routine treatment plus TMZ. After 3 months' therapy, greater pSOD, eCAT and GSH-Px (erythrocyte and plasma) activities and lower MDA activity were found with TMZ treatment compared with routine treatment. Plasma BNP levels were significantly lower in TMZ-treated patients and higher in the routine treatment group than in the control group. TMZ improved antioxidant levels, decreased oxidative stress and decreased plasma BNP levels in CCP patients.

Aged↗

PubMedDate not supplied

Gastric leiomyoblastoma: report of three cases.

Leiomyoblastoma is a rare smooth muscle tumor characterized by epithelioid cells with clear cytoplasms and an unknown biological behaviour. Since pre-operative diagnosis is difficult, the optimum strategy during the operation could be determined only by having a thorough knowledge about it beforehand. Leiomyoblastoma can be exogastric, intramural or endogastric. In the mostly benign exogastric leiomyoblastomas, total excision with resection of full thickness of gastric wall around the tumor is appropriate. Partial or total gastrectomy should be performed for intramural or endogastric tumors. We report one exogastric and two intramural gastric leiomyoblastoma cases treated in our hospital.

Adult↗